Literature DB >> 30039495

Changes in Australian Early-Career General Practitioners' Benzodiazepine Prescribing: a Longitudinal Analysis.

Parker Magin1,2, Amanda Tapley3,4, Adrian J Dunlop3,5, Andrew Davey3,4, Mieke van Driel6, Elizabeth Holliday3,7, Simon Morgan4, Kim Henderson3,4, Jean Ball7, Nigel Catzikiris3,4, Katie Mulquiney3,4, Neil Spike8,9, Rohan Kerr10, Simon Holliday3,5.   

Abstract

BACKGROUND: Australian and international guidelines recommend benzodiazepines and related drugs (hereafter "benzodiazepines") as second-line, short-term medications only. Most benzodiazepines are prescribed by general practitioners (GPs; family physicians). Australian GP registrars ("trainees" or "residents" participating in a post-hospital training, apprenticeship-like, practice-based vocational training program), like senior GPs, prescribe benzodiazepines at high rates. Education within a training program, and experience in general practice, would be expected to reduce benzodiazepine prescribing.
OBJECTIVE: To establish if registrars' prescribing of benzodiazepines decreases with time within a GP training program
DESIGN: Longitudinal analysis from the Registrar Clinical Encounters in Training multi-site cohort study PARTICIPANTS: Registrars of five of Australia's 17 Regional Training Providers. Analyses were restricted to patients ≥ 16 years. MAIN MEASURES: The main outcome factor was prescription of a benzodiazepine. Conditional logistic regression was used, with registrar included as a fixed effect, to assess within-registrar changes in benzodiazepine-prescribing rates. The "time" predictor variable was "training term" (6-month duration Terms 1-4). To contextualize these "within-registrar" changes, a mixed effects logistic regression model was used, including a random effect for registrar, to assess within-program changes in benzodiazepine-prescribing rates over time. The "time" predictor variable was "year" (2010-2015). KEY
RESULTS: Over 12 terms of data collection, 2010-2015, 1161 registrars (response rate 96%) provided data on 136,809 face-to-face office-based consultations. Two thousand six hundred thirty-two benzodiazepines were prescribed (for 1.2% of all problems managed). In the multivariable model, there was a significant reduction in within-program benzodiazepine prescribing over time (year) (p = < 0.001, OR = 0.94, CI = 0.90, 0.97). However, there was no significant change in 'within-registrar' prescribing over time (registrar Term) (p = 0.92, OR = 1.00 [95% CI = 0.94-1.06]).
CONCLUSIONS: Despite a welcome temporal trend for reductions in overall benzodiazepine prescribing from 2010 to 2015, there is still room for improvement and our findings suggest a lack of effect of specific GP vocational training program education and, thus, an opportunity for targeted education.

Entities:  

Keywords:  benzodiazepines; deprescriptions; education, medical, graduate; family practice; inappropriate prescribing

Mesh:

Substances:

Year:  2018        PMID: 30039495      PMCID: PMC6153232          DOI: 10.1007/s11606-018-4577-5

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  41 in total

1.  Antibiotic prescribing for respiratory infections: a cross-sectional analysis of the ReCEnT study exploring the habits of early-career doctors in primary care.

Authors:  Anthea Dallas; Parker Magin; Simon Morgan; Amanda Tapley; Kim Henderson; Jean Ball; John Scott; Neil Spike; Lawrie McArthur; Mieke van Driel
Journal:  Fam Pract       Date:  2014-10-31       Impact factor: 2.267

2.  Twenty-year trends in benzodiazepine dispensing in the Australian population.

Authors:  M M Islam; K M Conigrave; C A Day; Y Nguyen; P S Haber
Journal:  Intern Med J       Date:  2014-01       Impact factor: 2.048

3.  Future models of general practice training in Australia.

Authors:  Jon D Emery; Lesley P Skinner; Simon Morgan; Belinda J Guest; Alistair W Vickery
Journal:  Med J Aust       Date:  2011-06-06       Impact factor: 7.738

4.  Usage of benzodiazepines: A review.

Authors:  John Donoghue; Malcolm Lader
Journal:  Int J Psychiatry Clin Pract       Date:  2010-06       Impact factor: 1.812

5.  Benzodiazepines are Prescribed More Frequently to Patients Already at Risk for Benzodiazepine-Related Adverse Events in Primary Care.

Authors:  David S Kroll; Harry Reyes Nieva; Arthur J Barsky; Jeffrey A Linder
Journal:  J Gen Intern Med       Date:  2016-05-13       Impact factor: 5.128

6.  Opioids and Other Central Nervous System-Active Polypharmacy in Older Adults in the United States.

Authors:  Lauren B Gerlach; Mark Olfson; Helen C Kales; Donovan T Maust
Journal:  J Am Geriatr Soc       Date:  2017-05-03       Impact factor: 5.562

7.  Diagnosing infections: a qualitative view on prescription decisions in general practice over time.

Authors:  Ingunn Björnsdóttir; Karl G Kristinsson; Ebba Holme Hansen
Journal:  Pharm World Sci       Date:  2010-10-08

8.  Focus on early-career GPs: qualitative evaluation of a multi-faceted educational intervention to improve antibiotic prescribing.

Authors:  Laura Deckx; Sibyl Anthierens; Parker J Magin; Simon Morgan; Lawrie McArthur; Lucy Yardley; Anthea Dallas; Paul Little; Mieke L van Driel
Journal:  Fam Pract       Date:  2018-01-16       Impact factor: 2.267

9.  Trends in the Concomitant Prescribing of Opioids and Benzodiazepines, 2002-2014.

Authors:  Catherine S Hwang; Elizabeth M Kang; Cynthia J Kornegay; Judy A Staffa; Christopher M Jones; Jana K McAninch
Journal:  Am J Prev Med       Date:  2016-04-11       Impact factor: 5.043

10.  Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.

Authors:  Eric C Sun; Anjali Dixit; Keith Humphreys; Beth D Darnall; Laurence C Baker; Sean Mackey
Journal:  BMJ       Date:  2017-03-14
View more
  1 in total

1.  Capsule Commentary on Magin et al., Changes in Australian Early-Career General Practitioners' Benzodiazepine Prescribing: a Longitudinal Analysis.

Authors:  Benjamin J Oldfield
Journal:  J Gen Intern Med       Date:  2018-10       Impact factor: 5.128

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.